Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Pieternella J Lugtenburg, MD PhD, Josée M Zijlstra, MD, Jeanette K Doorduijn, MD PhD, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD PhD, Mels Hoogendoorn, MD PhD, Henriette W Berenschot, MD, Aart Beeker, MD, Fransje Valster, MD, Harry C. Schouten, MD PhD, Marleen Luten, MSc, Henk Hofwegen, Dana A Chitu, PhD, Rolf E Brouwer, MD PhD, Gustaaf W van Imhoff, MD PhD

Blood (2015) 126 (23): 2707.

https://doi.org/10.1182/blood.V126.23.2707.2707

Published: 2015

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Pier Luigi Zinzani, Bertrand Coiffier, MD PhD, John Radford, Dolores Caballero, Paul Fields, MD PhD, Martine ED Chamuleau, MD, Francesco d'Amore, Corinne Haioun, MD PhD, Catherine Thieblemont, MD PhD, Eva González Barca, MD PhD, Carlos Grande García, MD, Peter W Johnson, MD, Gustaaf W van Imhoff, MD PhD, Andrew Saunders, MD, Karen Dwyer, Franck Morschhauser, MD PhD

Blood (2014) 124 (21): 1763.

https://doi.org/10.1182/blood.V124.21.1763.1763

Published: 2014

Journal Articles

Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.

Zheng Liang, MD, Arjan Diepstra, MD PhD, Chuanhui Xu, MD PhD, Gustaaf W van Imhoff, MD, PhD, Wouter J Plattel, MD, Anke Van Den Berg, PhD, Lydia Visser, PhD

Blood (2012) 120 (21): 2640.

https://doi.org/10.1182/blood.V120.21.2640.2640

Published: 2012

Journal Articles

Treatment of Secondary Central Nervous System Lymphoma with Intrathecal Rituximab, High Dose Methotrexate and R-DHAP, Followed by Autologous Stem Cell Transplantation. A Phase II HOVON Study

Jeanette K Doorduyn, MD, PhD, Gustaaf W van Imhoff, MD, PhD, Kees CAGM van Montfort, PhD, Harry C Schouten, MD, PhD, Martyn Ronald Schaafsma, Johanna W. Baars, MD, PhD, Marie Jose Kersten, MD, PhD, Elly Lugtenburg, MD, PhD, Martin M.J. van den Bent, MD, PhD, Roelien Enting, Philip M.P. Poortmans, MD, PhD, Jacoline J.E.C. Bromberg, MD, PhD

Blood (2012) 120 (21): 306.

https://doi.org/10.1182/blood.V120.21.306.306

Published: 2012

Journal Articles

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Pieternella J Lugtenburg, MD, PhD, Josée M Zijlstra, MD, PhD, Jeanette K Doorduijn, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD, PhD, Mels Hoogendoorn, MD, PhD, Henriette W Berenschot, MD, PhD, Aart Beeker, MD, Fransje A Valster, MD, Harry C Schouten, MD, PhD, Marleen Luten, MSc, Dana A Chitu, Rolf E Brouwer, MD, PhD, Gustaaf W van Imhoff, MD, PhD

Blood (2012) 120 (21): 2729.

https://doi.org/10.1182/blood.V120.21.2729.2729

Published: 2012

Journal Articles

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

J.C. Kluin-Nelemans, MD, PhD, Marinus Van Marwijk Kooij, MD, PhD, P.J. Lugtenburg, MD, PhD, Pierre W Wijermans, Willem JL Van Putten, MSc, Gustaaf W van Imhoff, MD, PhD

Blood (2008) 112 (11): 1999.

https://doi.org/10.1182/blood.V112.11.1999.1999

Published: 2008

NARROW

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.

Treatment of Secondary Central Nervous System Lymphoma with Intrathecal Rituximab, High Dose Methotrexate and R-DHAP, Followed by Autologous Stem Cell Transplantation. A Phase II HOVON Study

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

Email alerts

ASH Publications

American Society of Hematology

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.

Treatment of Secondary Central Nervous System Lymphoma with Intrathecal Rituximab, High Dose Methotrexate and R-DHAP, Followed by Autologous Stem Cell Transplantation. A Phase II HOVON Study

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only